Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07108309) titled 'BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Biocad
Condition:
Triple Negative Breast Cancer
Intervention:
Biological: BCD-236
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: July 15, 2024
Target Sample Size: 124
Countries of Recruitment:
Belarus
Russian Federation
Belarus
Russian Federation
To know more, visit https://cl...